Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)
- 29 February 1996
- journal article
- Published by Elsevier BV in Leukemia Research
- Vol. 20 (2), 175-180
- https://doi.org/10.1016/0145-2126(95)00134-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometryBlood, 1994
- P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survivalBritish Journal of Haematology, 1994
- Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cellsBlood, 1993
- Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]Blood, 1992
- A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.Journal of Clinical Oncology, 1991
- Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivityBlood, 1991
- Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10)British Journal of Haematology, 1990
- AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trialBritish Journal of Haematology, 1989
- PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIALThe Lancet, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958